Maxim Group Upgrades Agile Therapeutics (AGRX) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AGRX Hot Sheet
Price: $1.51 --0%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Maxim Group analyst Caroline Palomeque upgraded Agile Therapeutics (NASDAQ: AGRX) from Hold to Buy with a price target of $1.00.
For an analyst ratings summary and ratings history on Agile Therapeutics click here. For more ratings news on Agile Therapeutics click here.
Shares of Agile Therapeutics closed at $0.50 yesterday.
You May Also Be Interested In
- Northland Upgrades Astera Labs (ALAB) to Outperform
- JPMorgan Upgrades Koito Manufacturing Co Ltd. (7276:JP) (KOTMF) to Overweight
- JPMorgan Upgrades KEPCO (015760:KS) (KEP) to Neutral
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
